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Background: Current anti-tuberculosis therapeutics are not sufficiently effective against drug-resistant
tuberculosis (DR-TB), and there is a need for new drugs and therapeutic approaches. It has been proposed
that repurposing clofazimine for DR-TB treatment might be one way to increase therapeutic options.
Methods: We conducted a systematic review of studies reporting on the efficacy and safety of clofazimine
as part of combination therapy for DR-TB. Six databases and six conference abstract sites were searched
from inception until April 2012. All studies involving the use of clofazimine in the treatment of DR-TB were
included.
Results: Twelve studies, comprising 3489 patients across 10 countries, were included in this review. Treatment
success ranged from 16.5% (95% CI 2.7%–38.7%) to 87.8% (95% CI 76.8%–95.6%), with an overall pooled
proportion of 61.96% achieving treatment success (95% CI 52.79%–71.12%) (t2 0.07). Mortality, treatment
interruptions, defaulting and adverse events were all in line with DR-TB treatment outcomes overall. The
most commonly reported adverse events were gastrointestinal disturbances and skin pigmentation.
Conclusions: The available evidence to date suggests that clofazimine could be considered as an additional
therapeutic option in the treatment of DR-TB. The optimal dose of clofazimine and duration of use require
further investigation.
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Introduction
The global burden of drug-resistant tuberculosis (DR-TB) is
growing. In 2010, an estimated 650000 cases of DR-TB were
reported worldwide. Alongside the rising prevalence of DR-TB,
there has been an increase in the spread of cases due to direct
contact with DR-TB patients, making DR-TB an epidemic in its
own right, especially in high-burden settings.1 Current guidelines
recommend at least 20 months of treatment, but current regi-
mens are toxic, poorly tolerated and inadequately effective,
with cure rates as low as 36% and default rates as high
as 50%.2 – 8
Given these challenges, and the growing number of cases
resistant to traditional tuberculosis (TB) drugs, there is a pressing
need for new drugs and approaches to treating DR-TB. However,
despite recent advances, therapeutic options are still limited. An
additional, complementary strategy is to repurpose existing
drugs.9 One such drug that has recently attracted interest for
use in the management of DR-TB is clofazimine. Clofazimine, a
member of the riminophenazine antibiotic class, was initially
studied for use in TB. However, after it was found to have poor
in vivo efficacy in guinea pig and simian models, its clinical devel-
opment was abandoned.2,10 Since then, clofazimine has been
found in both pre-clinical and clinical studies to be effective
against other mycobacterial diseases including those caused
by Mycobacterium leprae, Mycobacterium avium complex and
Mycobacterium kansasii.10 – 13 The effectiveness of clofazimine
against mycobacteria is thought to be due to its long half-life
(65–70 days), slow metabolic elimination, high concentration in
macrophages and rapid localization within phagocytes.9,14,15
Recent in vitro and in vivo trials show good efficacy and low toxicity
against DR-TB mycobacterial strains in mice.16
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Additionally, a number of recent clinical studies have noted
successful outcomes of shortened DR-TB treatment regimens
containing clofazimine. One recent study in Bangladesh reported
cure rates as high as 84.2% using a 9 month regimen containing
clofazimine.17 With these promising early results, clofazimine is
being considered for future new regimens, including through a
large multi-country, randomized control trial (the STREAM trial).
In order to frame recent studies within the broader evidence
base, we systematically reviewed the currently available clinical
data regarding the efficacy and safety of clofazimine in the treat-
ment of DR-TB.
Methods
This review was conducted according to PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-analyses) guidelines for reporting
systematic reviews.18
Search strategy and selection criteria
An initial protocol was developed (see Supplementary data, available at
JAC Online). Articles were searched in MEDLINE, EMBASE, Toxnet, Lilacs,
Clinicaltrials.gov and The Cochrane Central Register of Controlled Trials
(CENTRAL) electronic databases from inception until 18 May 2012. No
language, date, or geographical restrictions were applied. A search strat-
egy was developed combining search terms for ‘drug-resistance’, ‘tuber-
culosis’, ‘treatment outcomes’ and ‘clofazimine’ as exploded MESH
headings and free-text terms. Additionally, abstracts from the following
electronic conference sites until April 2012 were searched: Union World
Conference on Lung Health, Interscience Conference on Antimicrobial
Agents and Chemotherapy, Society of General Microbiology, British Thor-
acic Society, European Respiratory Society, American Thoracic Society.
Bibliographies of all relevant articles were also reviewed.
We sought randomized trials and observational studies involving
adults or children testing positive for DR-TB, including multidrug-resistant
TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), in which clofazi-
mine was used as part of the treatment regimen. If studies used clofazi-
mine for some patients and did not disaggregate outcomes overall,
authors were contacted for clarification. Given the anticipated paucity
of data, case series of five or more patients were also included. In the
case of duplicate publications from the same study site, the most com-
plete study was included.
Data extraction and management
Data were extracted from studies in duplicate by two researchers
(T. D. and N. F.). The primary outcome was treatment success; secondary
outcomes were death, failure, treatment stoppage/interruption, transfer,
default, and adverse events.
Treatment outcomes were recorded in line with adapted definitions of
those given in WHO guidelines,2 as follows: treatment success, defined as
the number of patients cured or who completed treatment combined;
death, defined as death from any cause while on treatment; failure,
defined as unsuccessful treatment as determined by positive cultures
at the end of the treatment regimen; stoppage/interruption, defined as
cessation or interruption of clofazimine-containing treatment regimen
because of adverse reactions; transfer, defined as transfer to another fa-
cility but known to be still under care; and default, defined as dropout
from the programme with unknown outcome. Study quality was
assessed using a modified Newcastle–Ottawa scale.19
A pre-defined data extraction form (Excel) was used to extract data
from each study selected for review. The following information was
recorded: study characteristics (authors, setting, study design and hospi-
talization), patient characteristics [age, populations, drug susceptibility
testing (DST) availability, drug resistance pattern, resistance to clofazi-
mine, previous TB regimens, HIV status and other comorbidities], treat-
ment characteristics (number of patients receiving clofazimine,
duration of whole treatment, duration of treatment involving clofazimine,
dose of clofazimine and partner drugs included in treatment regimen)
and treatment outcomes.
Data analysis
Point estimates and 95% CIs for the proportion of patients achieving
treatment outcomes were calculated, after stabilizing the variance of
the raw data using a Freeman–Tukey-type arcsine square-root trans-
formation. Estimates were then pooled for the primary outcome of treat-
ment success using a DerSimonian–Laird random effects model. We
report the t2 statistic as a measure of between-study variance. All ana-
lyses were conducted using Stata (version 12, Stata Corp., College
Station, TX, USA).
Results
The search strategy retrieved 1456 potential articles, of which
72 were screened as full-text articles and six were taken
through for analysis.17,20 – 24 One additional article was included
through bibliography screening,25 and five studies were included
as conference abstracts,26 – 30 giving a total of 12 studies com-
prising 3489 patients across 10 countries taken through for ana-
lysis (Figure 1). One study used six different treatment regimens
collapsed into two treatment arms: those treated with clofazi-
mine in the intensive phase, and those treated with clofazimine
throughout therapy. These two arms are reported separately,
giving 13 data sources overall.17
Study and treatment characteristics are summarized in
Tables 1 and 2. All studies were observational studies. Seven
studies included only patients with MDR-TB, two studies included
only patients with XDR-TB and three included both MDR-TB and
XDR-TB patients. Ten studies reported that DST was carried out
for all patients to confirm DR-TB, two studies specified that DST
was carried out for first-line anti-TB drugs and two carried out
DST for both first- and second-line drugs. No study reported
any resistance to clofazimine, although eight studies stated
that this was not tested.
Ten studies provided information on HIV status. In one study,
8% of patients (184/2305) were HIV positive.26 In three studies,
one patient was HIV positive.17,23,29 Another study reported that
some patients were HIV positive, but did not report numbers.25
The remaining studies all reported that all patients tested for
HIV were negative.22,24,27,28,30 Four studies listed patients
having additional comorbidities.17,24,25,29
Ten studies provided data on duration of therapy, which
ranged from 2 to 1729 days, and also provided data on the
length of therapy involving clofazimine. Nine of these studies
reported the same duration as for therapy overall; however, in
one study17 some patients were given clofazimine solely in
the intensive phase (3 months), while the rest received clofazi-
mine throughout treatment. Only five studies detailed the
dose of clofazimine: all five studies gave clofazimine as a daily
dose, which ranged between 50 and 300 mg. Seven studies
reported that patients were hospitalized for a part or all of
Systematic review
285
JAC
therapy; of these, two studies stated that patients were hospi-
talized for the intensive part of therapy.20,22 Three studies
reported that patients were hospitalized throughout
therapy.21,23,24 One study reported that hospitalization was
offered to patients, but was not mandatory.25 In one study,
80% (12/15) of patients were treated under direct observation
and hospitalized.29
Study quality
When methodological quality was assessed on the modified
Newcastle–Ottawa scale, most studies had a medium risk
for selection bias, a low risk for measurement bias and a
medium to high risk for bias in the assessment of outcomes
(Table 3).
Treatment outcomes
Treatment success, reported by 11 studies (3472 patients),
ranged from 16.5% (95% CI 2.7%–38.7%) to 87.8% (95% CI
76.8%–95.6%); the overall pooled proportion of treatment
success was 61.96% (95% CI 52.79%–71.12%) (t2 0.07)
(Figure 2). One large study contributed outcomes for 2305
patients. We investigated the potential influence of this single
study in a sensitivity analysis that excluded these data from
the meta-analysis; dropping this study did not importantly
change the overall estimate of treatment success (59.9%; 95%
CI 47.3%–72.5%). There was no apparent difference in the pro-
portion of patients achieving treatment success according to
whether the study was an article or an abstract and whether
or not patients had comorbidities. Data on dosage, duration of
therapy and hospitalization were too poorly reported to be
meaningfully assessed.
1456 abstracts identified and screened for possible inclusion
1371 excluded after screening of abstract and
title (inclusion criteria not met)
85 full-text articles selected
13 duplicates excluded
72 full-text articles screened for eligibility criteria
39 excluded:
13 review articles
17 pre-clinical articles
5 articles did not mention clofazimine
used specifically in therapy
1 article to do with leprosy
1 paper did not involve DR-TB patients
at start of study
2 comment pieces
4 additional full-text articles
identified from bibliographies
and similar citations
8 conference abstracts
found
45 studies assessing the use of clofazimine against DR-TB
33 excluded:
1 had no outcome data
14 had outcomes not disaggregated for
clofazimine
1 pre-clinical article
10 articles with fewer than 5 in a case series
2 review articles
2 did not involve clofazimine in treatment
regimen
1 comment piece
2 intermediary papers excluded
12 studies included for review
Figure 1. Identification of studies for inclusion.
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Table 1. Study characteristics
Study
Number
receiving
clofazimine Age (years) Setting Study design
Drug
resistance
pattern
Availability
of DST
Previous TB
regimens HIV status Other comorbidities
Goble et al.,
199321
17 .18 USA retrospective
cohort
study
MDR+XDR DST not stated not stated not stated
Senaratne,
200422
10 .18 Sri Lanka cohort study MDR DST for first-
line drugs
all had received previous TB
treatment; none had
previously received second-
line treatment
all HIV negative not stated
von der Lippe,
200623
10 .18 Norway prospective
cohort
study
MDR DST for first-
and second-
line drugs
8 patients had previous TB
treatment (details of the
previous TB regimen were
not known for 1 patient)
and 2 patients did not
report previous TB
treatment
1 HIV positive not stated
Oliveira,
200729
15/170a .18 Brazil retrospective
cohort
study
MDR DST not stated 1 HIV positive 2 diabetic
Dalcolmo,
200626
2305 .18 Brazil retrospective
cohort
study
MDR not stated not stated 184 HIV positive not stated
Prasad et al.,
200827
6 not statedb India retrospective
cohort
study
XDR DST not stated all HIV negative not stated
Mitnick et al.,
200825
447 not stated Peru retrospective
cohort
study
MDR+XDR DST median number of previous
regimens¼3
some (not
specified)
mean comorbidities¼61,
including low body mass
index/malnutrition, HIV,
diabetes, psychiatric
disorder, hepatitis or
cirrhosis, seizures/epilepsy,
cardiovascular disease,
renal insufficiency
Prasad et al.,
200928
14 not stateda India retrospective
cohort
study
XDR DST not stated all HIV negative not stated
Continued
System
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Table 1. Continued
Study
Number
receiving
clofazimine Age (years) Setting Study design
Drug
resistance
pattern
Availability
of DST
Previous TB
regimens HIV status Other comorbidities
Van Deun
et al.,
201017
427 .18 Bangladesh prospective
cohort
study
MDR DST nearly all patients enrolled on
OFX-based regimens and
.90% among the GAT-
treated patients had been
treated repeatedly with
first-line drugs for TB
1 HIV positive impaired liver function (1),
mild renal impairment (2),
diabetes mellitus (1)
Piubello et al.,
201130
44 not stated Niger cohort study
(design
unclear)
MDR not stated 43 had been treated for TB;
none had received second-
line treatment
0/39 not stated
Bonnet et al.,
201120
9 .18 Georgia prospective
cohort
study
MDR+XDR DST for first-
and second-
line drugs
INH+OFX+CPM/
KAN+EMB+CYS (2);
INH+OFX+CPM/
KAN+EMB+CYS+PAS (3);
INH+OFX+CPM/
KAN+EMB+PAS (3)
not stated not stated
Xu et al.,
201224
30 not stated China retrospective
cohort
study
MDR DST for first-
line drugs
all had previous history of TB
treatment
all HIV negative 9/30 had comorbidities:
hypertension (1), anaemia
(1), hyperprolactinaemia
(1), viral hepatitis B (1),
chronic obstructive
pulmonary disease (4),
bronchial asthma (1),
gallstones (1), superficial
gastritis (1), depressive
disorder (1),
pneumosilicosis (1),
pneumocardial disease (1),
diabetes mellitus (1)
CPM, capreomycin; CYS, cycloserine; EMB, ethambutol; GAT, gatifloxacin; INH, isoniazid; KAN, kanamycin; OFX, ofloxacin; PAS, para-aminosalicylic acid.
aAlthough 170 patients were given clofazimine, the paper detailed the outcomes of only 15 patients.
bAssumed adults as setting was a military hospital.
System
atic
review
2
8
8
Mortality during therapy, reported by 11 studies (3472
patients), ranged from 3.2% (95% CI 1.1%–6.4%) to 29.9%
(95% CI 10.3%–54.7%). Treatment failure, reported by eight
studies (3409 patients), ranged from 1.0% (95% CI 0.1%–2.6%)
to 63.4% (95% CI 38.3%–85.0%). Treatment stoppages/interrup-
tions, reported by four studies (446 patients), ranged from 6.3%
(95% CI 3.6%–9.7%) to 14.6% (95% CI 0.7%–41.8%). Defaulting
from treatment, reported by four studies (2966 patients),
ranged from 3.2% (95% CI 0.1%–10.3%) to 10.4% (95% CI
7.7%–13.4%). Finally, adverse events, reported by six studies
(3503 patients), ranged from 13.8% (95% CI 2.2%–32.9%) to
87.8% (95% CI 76.8%–95.6%). The most common adverse
events reported were gastrointestinal disturbances, e.g.
nausea, vomiting and abdominal pain, and skin pigmentation
(Table 4).
Discussion
This review has found that DR-TB patients treated with clofazimine
achieved a level of treatment success in line with treatment out-
comes for MDR-TB in general (62%).5,31 There was, however,
Table 2. Treatment characteristics
Study
Number
receiving
clofazimine
Dose of
clofazimine
(patients)
Duration of treatment
overall (patients)
Duration of
treatment with
clofazimine (patients)
Other drugs
included
in regimen Hospitalization
Goble et al.,
199321
17 300 mg daily not stated not stated range of first- and
second-line treatments
used
all hospitalized
Senaratne,
200422
10 not stated 3–4 month intensive
phase+variable
continuation phase
3–4 month intensive
phase at least
AMC, CIP, EMB, INH, STR not stated
von der Lippe,
200623
10 not stated 3–24 months 3–24 months EMB, INH, STR, CIP, CYS, LZD,
PAS, AMK, AMX, ETA, RIF,
PZA, CPM
all hospitalized
Oliveira,
200729
15/170 not stated not stated not stated AMK, OFX, TRD, EMB 12 (80%) underwent
DOTS
Dalcolmo,
200626
2305 not stated 18 months 18 months OFX, EMB, TRD, AMK, INH not stated
Prasad et al.,
200827
6 daily dose 20 months 20 months CYS, ETA, INH, CLR, LZD, PAS not stated
Mitnick et al.,
200825
447 25–600 mg daily 2–1729 days 2–1729 days INH, RIF, PZA, PAS, CIP, EMB,
STR, ETA, KAN, CYS, CLR,
OFX, AMC, RFB, CPM, LVX,
SPX, AMK, MXF
hospitalization available
but not mandatory
for all patients
Prasad et al.,
200928
14 daily dose 12–24 months 12–24 months CYS, ETA, INH, CLR, LZD, PAS not stated
Van Deun
et al.,
201017,a
183 ,33 kg (50 mg),
33–50 kg
(100 mg), .50 kg
(100 mg)
9–15 months 3 months KAN, OFX, EMB, INH, PZA,
PTH, GAT,
intensive phase
Van Deun
et al.,
201017,b
244 ,33 kg (50 mg),
33–50 kg
(100 mg), .50 kg
(100 mg)
9–15 months 9–15 months KAN, OFX, EMB, INH, PZA,
PTH, GAT,
intensive phase
Piubello et al.,
201130
44 not stated 12 months 12 months GAT, KAN, PTH, INH, PZA,
EMB
not stated
Bonnet et al.,
201120
9 200–300 mg
(majority
300 mg) daily (8),
1000 mg (1)
,3 months (3),
3–6 months (3),
12–15 months (3)
,3 months (3),
3–6 months (3),
12–15 months (3)
INH, OFX, CPM, AMC, CLR,
EMB, CYS, PAS
intensive phase
Xu et al.,
201224
30/44 100 mg daily mean+SD¼9.4+7.4 weeks mean+SD¼9.4+7.4
weeks
AMK, AMC, CPM, CLR, INH,
EMB, LZD, PAS, PZA, PTH,
RFB, RFP
all hospitalized
AMC, co-amoxiclav; AMK, amikacin; AMX, amoxicillin; CIP, ciprofloxacin; CLR, clarithromycin; CPM, capreomycin; CYS, cycloserine; DOTS, directly
observed therapy, short course; EMB, ethambutol; ETA, ethionamide; GAT, gatifloxacin; INH, isoniazid; KAN, kanamycin; LVX, levofloxacin; LZD,
linezolid; MXF, moxifloxacin; OFX, ofloxacin; PAS, para-aminosalicylic acid; PTH, prothionamide; PZA, pyrazinamide; RFB, rifabutin; RFP, rifapentine;
RIF, rifampicin; SPX, sparfloxacin; STR, streptomycin; TRD, terizidone.
aClofazimine used solely in the intensive phase.
bClofazimine used in intensive phase and continuation phase.
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substantial variation between studies in the proportion of patients
achieving treatment success. Four studies reported a success rate
of,40%, but these were smaller studies (≤15 patients), resulting
in wide CIs, and so this finding should be interpreted with caution.
Of note, two of these studies used clofazimine exclusively for the
treatment of patients with XDR-TB, which may explain the lower
treatment success rate of these studies. At the other extreme,
three studies reported a success rate of greater than 80%. These
studies included a relatively larger numbers of patients, and the
lower confidence limits for these point estimates were all above
60%. In one study, clofazimine replaced the more poorly accepted
and toxic prothionamide and was used in both the intensive and
continuation phases.17 Clofazimine’s use may have resulted in
fewer defaults from treatment, conferring a more successful
outcome.
One study used clofazimine for two different durations of
therapy.17 When clofazimine was used only in the intensive
phase, the proportion of patients achieving success was lower
(66%) than when clofazimine was used in both the intensive
phase and the continuation phase (87%), potentially suggesting
that longer duration of therapy with clofazimine may be asso-
ciated with a better outcome.
The number of deaths and failures are similarly in line with
reported outcomes for MDR-TB treatment overall.5,31 Failure of
treatment may be due to increasing resistance to drugs. Although
the majority of studies (10/12) stated that DST was carried out, no
studies tested for clofazimine, and only two specified that DST was
carried out for both first- and second-line drugs.20,23
HIV/DR-TB-co-infected patients are often considered to be
harder to treat and more likely to die.23,32 However, the study
reporting the highest number of HIV/DR-TB-co-infected patients
achieved a 65% success rate, in line with the overall findings.26
The proportion of adverse events was high, but again not im-
portantly different from adverse events reported by other DR-TB
treatment reviews.10,15 The majority of side effects reported by
the studies in this review were not considered to be serious
and could be managed through simple psychological support
and symptomatic palliation, an advantage over other second-
line therapeutics.21 This might explain the relatively low
number of treatment stoppages. Notably, none of the studies
reported cardiac toxicity.33
Adverse events are thought to be dose related.10,34 In one
study, lowering the dose of clofazimine to 100 mg every other
day was beneficial in managing the side effects of skin discolor-
ation in 20 patients and gastrointestinal side effects in
11 patients.24 A recent review noted that the reddish-
brown skin discoloration is gradually reversible upon cessation
of therapy.10 Nevertheless, another study noted that a patient
suffered from depression due to skin discoloration.24 Depending
on the extent of the skin discoloration, it might be prudent to
provide additional psychosocial support to patients undergoing
clofazimine treatment. Unfortunately, the information reported
Table 3. Quality assessment of included studies using a modified Newcastle–Ottawa scale
Study
Selection Measurement Outcome
representativeness
of the cohort to
the average
patient on MDR
treatment
ascertainment
of clofazimine
use
baseline
clofazimine
resistance
testing done
risk of bias
(high,
moderate,
low)
MDR
confirmed
through DST
risk of
bias
average
follow-up of
1 year post-
treatment
initiation
long-term
follow-up ,30%
among patients
on clofazimine risk of bias
Goble et al.,
199321
* — — medium * low * — medium (high)
Senaratne,
200422
* * — medium * low * — medium
von der Lippe,
200623
— * * medium * low * * low (medium)
Oliveira,
200729
* * — medium * low — — high
Dalcolmo,
200626
* * — medium — high * * low (medium)
Prasad et al.,
200827
* * — medium — high * * low (medium)
Mitnick et al.,
200825
* * — medium * low * — medium
Prasad et al.,
200928
* * — medium — high * * low (medium)
Van Deun
et al.,
201017
* * — medium * low * * low
Piubello et al.,
201130
* * — medium * low — * medium (high)
Bonnet et al.,
201120
* * — medium * low * — medium
Xu et al.,
201224
* * — medium * low — * medium
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by studies in this systematic review was insufficient to draw any
conclusions about dose-related outcomes.
There are several strengths and limitations to note. We
employed a broad search strategy, allowing analysis of 3489
patients from both articles and abstracts. However, outcomes
and key study and treatment characteristics were not consistent-
ly reported, limiting the number of analyses that could be done.
We limited our meta-analysis to the primary outcome of treat-
ment success; nevertheless, the substantial heterogeneity
between studies means that this estimate needs to be inter-
preted with caution.27,28 Publication bias is an ever-present
concern, but is unlikely to be important for this review given
the range of reported outcomes. The use of observational data
means that all results are potentially subject to unmeasured
confounding. Clofazimine was not the only drug used against
DR-TB in these studies, so outcomes cannot be definitely
ascribed to clofazimine. Finally, the inconsistent use of DST in
general, and the lack of reliable DST for clofazimine in particular,
means that it was not possible to determine whether observed
outcomes were influenced by pre-treatment resistance patterns.
Conclusions
Outcomes of clofazimine-containing regimens are in line with
drug-resistant (DR) treatment in general, and clofazimine
appears to be associated with a lower incidence of serious
adverse effects compared with other second-line therapeutics,
suggesting that clofazimine could potentially be considered as
an additional therapeutic agent for the treatment of DR-TB.
However, there are several important barriers to the use of clofa-
zimine. Currently, most of global supply of clofazimine is used for
and restricted to first-line management of leprosy.10,35,36 Despite
recent studies showing the clinical success of repurposing the
drug for DR-TB, there are issues accessing clofazimine for
Overall
Von der Lippe
Prasad
Van Deun
Senaratne
Bonnet
Prasad
Piubello
Xu
Author
Van Deun
Mitnick
Dalcolmo
2006
2008
2010
2004
2011
2009
2011
2012
Year
2010
2008
2006
61.96 (52.79–71.12)
86.69 (61.55–99.39)
35.55 (7.03–71.64)
Treatment success %
(95% CI)
66.03 (59.05–72.69)
31.73 (8.90–60.76)
34.92 (10.03–65.41)
16.53 (2.72–38.73)
87.80 (76.77–95.62)
62.91 (45.46–78.77)
87.14 (82.67–91.03)
59.93 (55.36–64.42)
65.16 (63.20–67.09)
10
6
183
10
9
14
44
30
244
447
2305
Number treated with
clofazimine
9
2
121
3
3
2
39
19
213
268
1502
Number achieving
treatment success
Percentage 
0 20 40 60 80 100
Figure 2. Proportion of patients achieving treatment success.
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DR-TB.37,38 At an annual cost of $114 (300 mg daily) per patient,
clofazimine could be potentially more affordable than other
DR-TB drugs.39 A meeting at the WHO in Geneva in March
2012 highlighted that clofazimine is one of the two most import-
ant second-line drugs and needs to be made more accessible for
use in low-resource settings.37
This review points to several directions for future research.
Firstly, the optimum duration and dose of clofazimine therapy
needs to be established. Although clofazimine is planned to be
included in a number of upcoming clinical trials for DR-TB,
none will specifically assess clofazimine’s action in a treatment
regimen for DR-TB. Secondly, more pre-clinical studies assessing
the potential synergistic action that clofazimine can have with
other TB drugs would be beneficial. Finally, more data on clofa-
zimine use in DR-TB-infected subpopulations such as HIV-
positive patients and children are needed.
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